BSE Live
Apr 08, 16:01Prev. Close
1441.40
Open Price
1442.20
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Apr 08, 15:58Prev. Close
1442.20
Open Price
1463.50
Bid Price (Qty.)
1445.00 (258)
Offer Price (Qty.)
0.00 (0)
| Cash Flow of Ipca Laboratories (in Rs. Cr.) | Mar 15 | Mar 14 | Mar 13 | Mar 12 | Mar 11 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 357.73 | 629.09 | 461.37 | 368.94 | 343.70 | |
| Net CashFlow From Operating Activities | 442.41 | 527.08 | 386.85 | 222.33 | 214.57 | |
| Net Cash Used In Investing Activities | -672.78 | -374.37 | -263.42 | -230.45 | -198.84 | |
| Net Cash Used From Financing Activities | 254.99 | -138.36 | -78.13 | 6.49 | -16.80 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 2.22 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | 24.62 | 14.35 | 45.30 | 0.59 | -1.07 | |
| Cash And Cash Equivalents Begin of Year | 67.46 | 53.11 | 7.81 | 7.22 | 8.29 | |
| Cash And Cash Equivalents End Of Year | 92.08 | 67.46 | 53.11 | 7.81 | 7.22 |
31.03.2026
06.03.2026
Buy Ipca Laboratories; target of Rs 1800: Prabhudas Lilladher
18.02.2026
Buy Ipca Laboratories; target of Rs 1710: Prabhudas Lilladher
17.02.2026
26.11.2025
Ipca Labs Consolidated September 2025 Net Sales at Rs 2,556.50 crore, up 8.56% Y-o-Y
24.11.2025
Ipca Labs Standalone September 2025 Net Sales at Rs 1,930.32 crore, up 6.59% Y-o-Y
05.09.2025
Ipca Labs Standalone June 2025 Net Sales at Rs 1,746.90 crore, up 11.56% Y-o-Y
10.06.2025
Ipca Labs Standalone March 2025 Net Sales at Rs 1,638.44 crore, up 8.46% Y-o-Y
13.07.2022
Ipca Lab Q1 PAT may dip 41.4% YoY to Rs 179.8 cr: ICICI Direct
08.07.2022
Ipca Laboratories Q1 PAT may dip 36.5% YoY to Rs 194.9 cr: Prabhudas Lilladher
14.04.2022
Ipca Laboratories Q4 PAT may dip 12% YoY to Rs 141.9 cr: Prabhudas Lilladher
13.01.2022
Ipca Laboratories Q3 PAT may dip 32.4% YoY to Rs 179.6 cr: Prabhudas Lilladher
08.04.2026
Indian CDMOs face tariff exposure via patented drug supply chains
08.04.2026
08.04.2026
07.04.2026
Kiran Mazumdar‑Shaw calls for new IPO rules to unlock India’s innovation potential in life sciences
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth